Synergistic Antitumor Activity of Curcumin and the PARP1 Inhibitor PJ34 in Platinum-Sensitive and Resistant Ovarian Cancer Cells

This preclinical provides evidence that combined PARP1 inhibition and curcumin treatment can exert synergistic antitumor effects in ovarian cancer models, including relatively platinum-resistant disease, through the coordinated suppression of proliferation, induction of regulated apoptosis, and inhibition of migration. The integration of quantitative synergy analysis, 3D spheroid validation, and ROS-rescue experiments provides functionally supported, hypothesis-generating mechanistic insight and supports further evaluation of PARP inhibitor-curcumin combinations as a mechanistic proof-of-concept in advanced preclinical models.